Iwaniec UT, Turner RT (2016) Influence of body weight on bone mass, architecture and turnover. J Endocrinol. https://doi.org/10.1530/JOE-16-0089

Article  PubMed  PubMed Central  Google Scholar 

Oftadeh R, Perez-Viloria M, Villa-Camacho JC, Vaziri A, Nazarian A (2015) Biomechanics and mechanobiology of trabecular bone: a review. J Biomech Eng. https://doi.org/10.1115/1.4029176

Article  PubMed  PubMed Central  Google Scholar 

Parfitt AM (2001) The bone remodeling compartment: a circulatory function for bone lining cells. J Bone Miner Res. https://doi.org/10.1359/jbmr.2001.16.9.1583

Article  PubMed  Google Scholar 

Seeman E, Delmas PD (2006) Bone quality – the material and structural basis of bone strength and fragility. N Engl J Med. https://doi.org/10.1056/NEJMra053077

Article  PubMed  Google Scholar 

Tobeiha M, Moghadasian MH, Amin N, Jafarnejad S (2020) RANKL/RANK/OPG Pathway: a mechanism involved in exercise-induced bone remodeling. Biomed Res Int. https://doi.org/10.1155/2020/6910312

Article  PubMed  PubMed Central  Google Scholar 

Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ (1999) Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endroc Ver. https://doi.org/10.1210/edrv.20.3.0367

Article  Google Scholar 

Kaneda T, Nojima T, Nakagawa M, Ogasawara A, Kaneko H, Sato T, Mano H, Kumegawa M, Hakeda Y (2000) Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-Kappa B ligand and macrophage-colonystimulating factor. J Immunol. https://doi.org/10.4049/jimmunol.165.8.4254

Article  PubMed  Google Scholar 

Drake MT, Cremers SC (2010) Bisphosphonate therapeutics in bone disease: the hard and soft data on osteoclast inhibition. Mol Interv. https://doi.org/10.1124/mi.10.3.5

Article  PubMed  Google Scholar 

Kuźnik A, Październiok-Holewa A, Jewula P, Kuźnik N (2020) Bisphosphonates-much more than only drugs for bone diseases. Eur J Pharmacol. https://doi.org/10.1016/j.ejphar.2019.172773

Article  PubMed  Google Scholar 

Aapro M, Saad F, Costa L (2010) Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases. Oncologist. https://doi.org/10.1634/theoncologist.2007-0245

Article  PubMed  PubMed Central  Google Scholar 

Deardorff WJ, Cenzer I, Nguyen B, Lee SJ (2022) Time to benefit of bisphosphonate therapy for the prevention of fractures among postmenopausal women with osteoporosis: a meta-analysis of randomized clinical trials. JAMA Intern Med. https://doi.org/10.1001/jamainternmed.2021.6745

Article  PubMed  PubMed Central  Google Scholar 

Perazella MA, Markowitz GS (2008) Bisphosphonate nephrotoxicity. Kidney Int. https://doi.org/10.1038/ki.2008.356

Article  PubMed  Google Scholar 

So A, Chin J, Fleshner N, Saad F (2012) Management of skeletal-related events in patients with advanced prostate cancer and bone metastases: incorporating new agents into clinical practice. Can Urol Assoc J. https://doi.org/10.5489/cuaj.12149

Article  PubMed  PubMed Central  Google Scholar 

Ruggiero SL, Dodson TB, Aghaloo T, Carlson ER, Ward BB, Kademani D (2022) American association of oral and maxillofacial surgeons’ position paper on medication-related osteonecrosis of the jaws-2022 update. J Oral Maxillofac Surg. https://doi.org/10.1016/j.joms.2022.02.008

Article  PubMed  Google Scholar 

Rogers MJ, Mönkkönen J, Munoz MA (2020) Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 139:115493. https://doi.org/10.1016/j.bone.2020.115493

Article  CAS  PubMed  Google Scholar 

Pazianas M (2011) Osteonecrosis of the jaw and the role of macrophages. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djq516

Article  PubMed  Google Scholar 

Coxon FP, Thompson K, Roelofs AJ, Ebetino FH, Rogers MJ (2008) Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells. Bone. https://doi.org/10.1016/j.bone.2007.12.225

Article  PubMed  Google Scholar 

Francis MD, Russell RGG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. https://doi.org/10.1126/science.165.3899.1264

Article  PubMed  Google Scholar 

Benedict JJ (1982) The physical chemistry of the diphosphonates— its relationship to their medical activity. In: Donath A, Courvoiser B (eds) Symposium CEMO (Centre d’Etude des Maladies Ostéoarticulaires de Genève) IV. Diphosphonates and bone. Editions Médecine at Hygiène, Geneva, pp 1–19.

Ebrahimpour A, Francis MD (1995) Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies. In: Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (eds) Bisphosphonate on bones. Elsevier, Amsterdam, pp 125–136

Google Scholar 

Bijvoet OLM, Fleisch HA, Canfield RE, Russell RGG (eds) (1995) Bisphosphonate on bones. Elsevier, Amsterdam

Google Scholar 

Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. https://doi.org/10.1007/s00198-007-0540-8

Article  PubMed  Google Scholar 

Maruotti N, Corrado A, Neve A, Cantatore FP (2012) Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol. https://doi.org/10.1007/s00228-012-1216-7

Article  PubMed  Google Scholar 

Jensen PR, Andersen TL, Chavassieux P, Roux JP, Delaisse JM (2021) Bisphosphonates impair the onset of bone formation at remodeling sites. Bone 145:115850. https://doi.org/10.1016/j.bone.2021.115850

Article  CAS  PubMed  Google Scholar 

Hadad H, Matheus HR, Chen JE, Jounaidi Y, Souza FÁ, Guastaldi FP (2023) Dose-dependent effects of zoledronic acid on the osteogenic differentiation of human bone marrow stem cells (hBMSCs). J Stomatol Oral Maxillofac Surg. https://doi.org/10.1016/j.jormas.2023.101479

Article  PubMed  Google Scholar 

Corrado A, Neve A, Maruotti N, Gaudio A, Marucci A, Cantatore FP (2010) Dose-dependent metabolic effect of zoledronate on primary human osteoblastic cell cultures. Clin Exp Rheumatol 28(6):873–876

CAS  PubMed  Google Scholar 

Walter C, Pabst A, Ziebart T, Klein MO, Al-Nawas B (2011) Bisphosphonates affect migration ability and cell viability of HUVEC, fibroblasts and osteoblasts in vitro. Oral Dis. https://doi.org/10.1111/j.1601-0825.2010.01720.x

Article  PubMed  Google Scholar 

Lang M, Zhou Z, Shi L, Niu J, Xu S, Lin W, Chen Z, Wang Y (2016) Influence of zoledronic acid on proliferation, migration, and apoptosis of vascular endothelial cells. Br J Oral Maxillofac Surg. https://doi.org/10.1016/j.bjoms.2016.05.030

Article  PubMed  Google Scholar 

Gao SY, Zheng GS, Wang L, Liang YJ, Zhang SE, Lao XM, Li K, Liao GQ (2017) Zoledronate suppressed angiogenesis and osteogenesis by inhibiting osteoclasts formation and secretion of PDGF-BB. PLoS One. https://doi.org/10.1371/journal.pone.0179248

Article  PubMed  PubMed Central  Google Scholar 

Allen MR, Burr DB (2009) The pathogenesis of bisphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. J Oral Maxillofac Surg. https://doi.org/10.1016/j.joms.2009.01.007

Article  PubMed  Google Scholar 

Baron R, Ferrari S, Russell RG (2011) Denosumab and bisphosphonates: different mechanisms of action and effects. Bone. https://doi.org/10.1016/j.bone.2010.11.020

Article  PubMed  PubMed Central  Google Scholar 

Anna Di Vito E, Chiarella F, Baudi P, Scardamaglia A, Antonelli D, Giudice T, Barni L, Fortunato A. Giudice (2020) Dose-dependent effects of zoledronic acid on human periodontal ligament stem cells: an in vitro pilot study. Cell Trans. https://doi.org/10.1177/0963689720948497

Article  Google Scholar 

Huang X, Huang S, Guo F, Xu F, Cheng P, Ye Y, Dong Y, Xiang W, Chen A (2016) Dose-dependent inhibitory effects of zoledronic acid on osteoblast viability and function in vitro. Mol Med Rep. https://doi.org/10.3892/mmr.2015.4627

Article  PubMed  PubMed Central